SAN

Sanofi (SAN)

Sanofi

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:EU:SAN

1 2 3 4 5 6 7 8 9 10 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/06/04	05:15	GlobeNewswire Inc.	Communiqué de presse : ASCO : Sarclisa, en association avec un protocole VRd, est le premier anti-CD38 permettant d’améliorer significativement la survie sans progression des patients […]	EU:SAN	Sanofi
2024/06/04	05:15	GlobeNewswire Inc.	Press Release: ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival in combination with VRd for newly diagnosed transplant-ineligible multiple myeloma in phase 3	EU:SAN	Sanofi
2024/06/04	05:15	GlobeNewswire Inc.	Press Release: ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival in combination with VRd for newly diagnosed transplant-ineligible multiple myeloma in phase 3	EU:SAN	Sanofi
2024/05/31	19:00	GlobeNewswire Inc.	Communiqué de presse : Sanofi lance son plan mondial 2024 d’actionnariat salarié	EU:SAN	Sanofi
2024/05/31	19:00	GlobeNewswire Inc.	Press Release: Sanofi launches 2024 global Employee Stock Purchase Plan	EU:SAN	Sanofi
2024/05/31	19:00	GlobeNewswire Inc.	Press Release: Sanofi launches 2024 global Employee Stock Purchase Plan	EU:SAN	Sanofi
2024/05/31	14:05	GlobeNewswire Inc.	Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD	EU:SAN	Sanofi
2024/05/31	14:05	GlobeNewswire Inc.	Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPD	EU:SAN	Sanofi
2024/05/31	14:05	GlobeNewswire Inc.	Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPD	EU:SAN	Sanofi
2024/05/31	14:05	GlobeNewswire Inc.	Communiqué de presse : Le CHMP recommande l'approbation de Dupixent dans l'UE pour le traitement des patients atteints de BPCO	EU:SAN	Sanofi
2024/05/31	14:00	GlobeNewswire Inc.	Press Release: Update on FDA priority review of Dupixent for the treatment of COPD patients with type 2 inflammation	EU:SAN	Sanofi
2024/05/31	14:00	GlobeNewswire Inc.	Communiqué de presse : Point d’actualité sur l’examen prioritaire de la FDA relatif au Dupixent pour le traitement de la BPCO avec inflammation de type 2	EU:SAN	Sanofi
2024/05/31	14:00	GlobeNewswire Inc.	Press Release: Update on FDA priority review of Dupixent for the treatment of COPD patients with type 2 inflammation	EU:SAN	Sanofi
2024/05/30	22:01	GlobeNewswire Inc.	Press Release: Sanofi completes acquisition of Inhibrx, Inc.	EU:SAN	Sanofi
2024/05/30	22:01	GlobeNewswire Inc.	Press Release: Sanofi completes acquisition of Inhibrx, Inc.	EU:SAN	Sanofi
2024/05/30	22:01	GlobeNewswire Inc.	Communiqué de presse : Sanofi finalise l’acquisition d’Inhibrx, Inc.	EU:SAN	Sanofi
2024/05/27	14:00	GlobeNewswire Inc.	Press Release: Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible newly diagnosed multiple myeloma	EU:SAN	Sanofi
2024/05/27	14:00	GlobeNewswire Inc.	Press Release: Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible newly diagnosed multiple myeloma	EU:SAN	Sanofi
2024/05/27	14:00	GlobeNewswire Inc.	Communiqué de presse : La FDA accorde un examen prioritaire au Sarclisa pour le traitement des patients atteints d’un myélome multiple nouvellement diagnostiqué non éligibles à une transplantation	EU:SAN	Sanofi
2024/05/21	14:30	GlobeNewswire Inc.	Press Release: Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration	EU:SAN	Sanofi
2024/05/21	14:30	GlobeNewswire Inc.	Communiqué de presse : Sanofi, Formation Bio et OpenAI annoncent une coopération de première classe autour de l’IA	EU:SAN	Sanofi
2024/05/21	14:30	GlobeNewswire Inc.	Press Release: Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration	EU:SAN	Sanofi
2024/05/21	05:54	GlobeNewswire Inc.	Sanofi: Information concerning the total number of voting rights and shares - April 2024	EU:SAN	Sanofi
2024/05/21	05:54	GlobeNewswire Inc.	Sanofi: Informations relatives au nombre de droits de vote et d'actions - Avril 2024	EU:SAN	Sanofi
2024/05/21	03:15	GlobeNewswire Inc.	Communiqué de presse : Présentation à l’ATS et publication dans le NEJM des données de dernière heure de l’étude confirmatoire de phase III NOTUS relative à Dupixent® dans le traitement de la BPCO	EU:SAN	Sanofi
2024/05/21	03:15	GlobeNewswire Inc.	Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM	EU:SAN	Sanofi
2024/05/21	03:15	GlobeNewswire Inc.	Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM	EU:SAN	Sanofi
2024/05/13	14:00	GlobeNewswire Inc.	Communiqué de presse : Sanofi investit plus d’un milliard d’euros supplémentaires dans la production de médicaments en France, en plus des 2,5 milliards d’euros déjà engagés dans de grands projets de souveraineté sanitaire	EU:SAN	Sanofi
2024/05/13	14:00	GlobeNewswire Inc.	Press Release: Sanofi adds over €1 billion for biomanufacturing to €2.5 billion already committed in major projects in France to support health sovereignty	EU:SAN	Sanofi
2024/05/13	14:00	GlobeNewswire Inc.	Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP)	EU:SAN	Sanofi